These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16946199)

  • 21. The uncertainty principle and industry-sponsored research.
    Djulbegovic B; Lacevic M; Cantor A; Fields KK; Bennett CL; Adams JR; Kuderer NM; Lyman GH
    Lancet; 2000 Aug; 356(9230):635-8. PubMed ID: 10968436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mega-trials for blockbusters.
    Ioannidis JP
    JAMA; 2013 Jan; 309(3):239-40. PubMed ID: 23321760
    [No Abstract]   [Full Text] [Related]  

  • 23. Methodological concerns in a trial of ziprasidone and olanzapine.
    Carnahan RM; Perry PJ
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
    [No Abstract]   [Full Text] [Related]  

  • 24. Quality of reporting controlled clinical trials on treatment of the acute mania phase of bipolar disorder with new antipsychotic drugs.
    Arbaizar B; Gómez-Acebo I; Llorca J
    Pharmacopsychiatry; 2008 Nov; 41(6):240-1. PubMed ID: 19067261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Newer antipsychotics in treatment-resistant schizophrenia.
    Marder SR
    Biol Psychiatry; 1999 Feb; 45(4):383-4. PubMed ID: 10071705
    [No Abstract]   [Full Text] [Related]  

  • 27. Comments on "Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II Study)" by Dr Thase and colleagues.
    Rifkin AE
    J Clin Psychopharmacol; 2008 Jun; 28(3):367; author reply 368. PubMed ID: 18480708
    [No Abstract]   [Full Text] [Related]  

  • 28. Commentary: how the doctor can counter commercial bias in the dissemination of pharmacotherapeutic knowledge.
    Carpenter WT
    J Nerv Ment Dis; 2002 Sep; 190(9):593-6. PubMed ID: 12357092
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
    Polsky D; Doshi JA; Bauer MS; Glick HA
    Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Keeping 'em honest: the current crisis of confidence in antidepressants.
    Teboul E
    J Clin Psychiatry; 2011 Jul; 72(7):1015; author reply 1015-6. PubMed ID: 21824461
    [No Abstract]   [Full Text] [Related]  

  • 31. Risperidone and clozapine for treatment-resistant schizophrenia.
    Meltzer HY
    Am J Psychiatry; 1999 Jul; 156(7):1126-7; author reply 1127-8. PubMed ID: 10401484
    [No Abstract]   [Full Text] [Related]  

  • 32. Publication bias and the efficacy of antidepressants.
    Mathew SJ; Charney DS
    Am J Psychiatry; 2009 Feb; 166(2):140-5. PubMed ID: 19188290
    [No Abstract]   [Full Text] [Related]  

  • 33. Olanzapine on trial.
    Capehart BP; Holsinger T
    Am J Psychiatry; 1998 Jan; 155(1):152; author reply 153-5. PubMed ID: 9433357
    [No Abstract]   [Full Text] [Related]  

  • 34. [Are treatment effects or adverse effects of significance for the association between financing and conclusions in randomized trials?].
    Als-Nielsen BE; Chen W; Gluud CN; Gluud LL
    Ugeskr Laeger; 2004 Apr; 166(18):1676-8. PubMed ID: 15174406
    [No Abstract]   [Full Text] [Related]  

  • 35. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research.
    Freemantle N; Marston L; Walters K; Wood J; Reynolds MR; Petersen I
    BMJ; 2013 Nov; 347():f6409. PubMed ID: 24217206
    [No Abstract]   [Full Text] [Related]  

  • 36. Avoiding legal and ethical pitfalls of industry-sponsored research: the co-existence of research, scholarship, and marketing in the pharmaceutical industry.
    Dorfman HL; Reig LP
    Food Drug Law J; 2004; 59(4):595-615. PubMed ID: 15880876
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparative effectiveness of antipsychotic drugs.
    Gupta S
    Am J Psychiatry; 2003 Mar; 160(3):591; author reply 592-3. PubMed ID: 12611855
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacotherapy of first-episode schizophrenia.
    Rosenheck RA
    Lancet; 2008 Mar; 371(9618):1048-9. PubMed ID: 18374824
    [No Abstract]   [Full Text] [Related]  

  • 39. Review of randomized controlled trials: issues to consider when designing a trial.
    Pandis N
    Am J Orthod Dentofacial Orthop; 2013 Jun; 143(6):905-7. PubMed ID: 23726342
    [No Abstract]   [Full Text] [Related]  

  • 40. Risperidone and clozapine for treatment-resistant schizophrenia.
    Dunayevich E; Chatterjee A
    Am J Psychiatry; 1999 Jul; 156(7):1127; author reply 1127-8. PubMed ID: 10401486
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.